As a well-known fair for pharmaceuticals, home care medical equipment and healthcare products with relevant technology and services, the 81st Pharmchina was opened at the National Exhibition and Convention Center in Shanghai on May 13th. It provides an ideal platform for company branding and trade in Mainland China and thus attracts tens of thousands of pharmaceutical companies and professionals across the country.
Both Linuo Pharma and Hongjitang Pharma made the most of the opportunity to present their products and enhance their brand awareness. With its existing product portfolio, i.e. CNS drugs, anti-cancer drugs and cardiovascular drugs, Linuo Pharma’s team associated with interested parties. It also discussed the market trend with representatives from its strategic partners nationwide and informed them of the R&D progress of new products.
With the industrial transition from Made in China to Created in China, the combination of inheritance and innovation is the only feasible approach for the development of established TCM companies like Hongjitang. Equipped with a highly efficient quality management system, Hongjitang has achieved reliable automatic production, packaging and traceability. The R&D and industrialization of artificial muscone won Hongjitang the first prize for National Science and Technology Progress in 2015. Its new product to be launched soon for the treatment of pulmonary fibrosis shall be a breakthrough in this area and a new profit point for the company.
Furthermore, Hongjitang Pharma works closely with renowned TCM institutes for the R&D of classical recipes and new indications of existent TCM products. The innovation-driven development strategy shall guarantee Hongjitang and partners involved a sustainable growth in the TCM market.